Compare STOK & WLTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STOK | WLTH |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | 391 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2019 | N/A |
| Metric | STOK | WLTH |
|---|---|---|
| Price | $30.48 | $8.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $39.20 | $12.86 |
| AVG Volume (30 Days) | 469.4K | ★ 2.0M |
| Earning Date | 05-08-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.73 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $184,420,000.00 | N/A |
| Revenue This Year | N/A | $10.58 |
| Revenue Next Year | $77.49 | $23.43 |
| P/E Ratio | ★ N/A | $10.57 |
| Revenue Growth | ★ 404.50 | N/A |
| 52 Week Low | $11.17 | $7.20 |
| 52 Week High | $40.22 | $14.12 |
| Indicator | STOK | WLTH |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 29.99 |
| Support Level | $30.34 | $8.29 |
| Resistance Level | $35.11 | $9.32 |
| Average True Range (ATR) | 1.43 | 0.61 |
| MACD | 0.17 | -0.30 |
| Stochastic Oscillator | 61.65 | 11.02 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Wealthfront Corp is a product-driven technology company that built a financial solutions platform for digital natives. The platform is designed to address the needs of the wealth builders within these generations. Its business model is designed to optimize for clients' success. The focus on delivering fully automated services results in being one of the lowest cost producers in each category in which participate. The group generates revenue from cash management and investment advisory products. Cash management revenue is earned from fees received for the delivery of cash management services, including the cash sweep program.